Relmada airs its complaints and lawsuits against Laidlaw


Posted by LLJ43 | Posted in Investing | Posted on 04-11-2016

Relmada Therapeutics is a clinical drug company. In January 2016, it filed a lawsuit and complaint against Laidlaw and Company. The trial involved the alleged leakage of confidential information. The leaked information violated Relmada’s policy as an investment bank. Relmada further accused Laidlaw of charging excessive fees and producing misleading information. Case proceedings were heard at the Nevada District Court.

The whole incident started on December 2015. Relmada brought an idea of adding new investors to Laidlaw. Laidlaw proposed to have the discussion held in a private manner. Laidlaw introduced Relmada to investors they recommended. Interactions with these investors led to leaked information and the lawsuit. Laidlaw allegedly sent a letter to the Securities and Exchange Commissions. The letter disclosed Relmada’s confidential information. The leaked information violates the confidentiality agreement.

Mathew Eitner and James Ahern lead Laidlaw and Company. Mathew Eitner serves as the CEO while James Ahern is the senior managing partner. Laidlaw has been in operation for more than 170 years. It has amassed years of experience in investment and securities. It has hundreds of offices scattered across Europe and the United States. Laidlaw strives to become a leading customer base. It is one of the largest companies in the investment and securities arena.